BullFrog AI Receives U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
(24/7 MARKET NEWS) – BullFrog AI Holdings, Inc. (NASDAQ:BFRGW) reported, this morning, that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 11,712,435 on August 1, 2023, which should protect the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases.
BullFrog AI is trading at $4.39, up $0.93 (+26.88%), on 1.16M premarket shares traded.
Its 52-week range is $2.47 to $9.50. This has only traded for about 5 months, so it doesn’t have much history, but in that short timeframe it’s had some big swings, so let’s see if this is the beginning of another run.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.